Autumn brings a chill in the air – and the start of another season of respiratory illnesses, which can be especially hard for older adults. Although vaccine recommendations have been in flux, the ...

Adults who are admitted to the hospital are often inappropriately diagnosed with — and treated for — pneumonia, new research suggests. These misdiagnosed adults almost always receive a full course of ...

Company Expects to Report Topline Data from OPUS-3 Trial and OPUS-2 Phase 3 Trial Evaluating Concomitant Administration of VAX-31 and a Seasonal Influenza Vaccine in First Half of 2027 ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory ...

The FDA approved a 21-valent pneumococcal conjugate vaccine (Capvaxive) for preventing invasive pneumococcal disease and pneumococcal pneumonia in adults, Merck announced on Monday. Specifically ...

Dear Doctors: I just turned 57, and my doctor is now saying that I should get vaccinated for pneumonia. The only time I ever had pneumonia was one time when I had a bad case of the flu. Why isn’t he ...

Researchers at the University of Oulu have identified genes that increase susceptibility to pneumonia. Alongside inherited risk factors, smoking and higher body mass were also found to raise the risk ...

NEW ORLEANS — In the U.S., pneumonia is the most common cause of hospital admissions after women having babies. Half of those hospitalized for pneumonia are young and middle-aged adults. With the ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneumococcal ...

(The Conversation is an independent and nonprofit source of news, analysis and commentary from academic experts.) Laurie Archbald-Pannone, University of Virginia (THE CONVERSATION) Autumn brings a ...